Strumento inattivo

Altre lingue 3SBio Inc. (ADR) Nasdaq

Azioni

US88575Y1055

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

22/04	3Sbio Inc. annuncia cambiamenti nella gestione	CI
12/04	3SBio Inc. Approva l'iniezione di trombopoietina umana ricombinante (Tpiao) per l'indicazione ITP pediatrica	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

3Sbio Inc. Announces Management Changes	22/04
3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	15/04
3SBio Inc. Approves Recombinant Human Thrombopoietin Injection for Pediatric ITP Indication	12/04
3SBio Inc. commences an Equity Buyback for 243,892,041 shares, representing 10% of its issued share capital, under the authorization approved on June 20, 2023.	27/03
3SBio's 2023 Profit Falls 19%, EPS Misses Estimates	21/03
3SBio Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on August 05, 2024	20/03
3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
China's NMPA Gives 3SBio Permission to Sell Anti-Dandruff Product	08/01
Mandi Foam of 3SBio Inc. Approves for Market Launch	08/01
Venus Medtech Names Former 3SBio Finance Chief as CFO	04/01
3SBio Secures Exclusive License to CStone's Anti-Tumor Drug in China	02/11
3SBio's H1 Attributable Profit Rises, Beats EPS Estimates	25/08/23
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	25/08/23
3SBio : 2023 Interim Results Presentation	24/08/23
3SBio Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	24/08/23
3SBio Hires Former JPMorgan Exec as CFO	31/07/23
3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer	28/07/23
3SBio Rolls Out Pruritus Medication in China	06/07/23
3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market	05/07/23
3SBio Inc.'s Equity Buyback announced on July 15, 2022, has expired.	20/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue 3SBio Inc. (ADR) Nasdaq

Azioni

US88575Y1055

Altre lingue

Filtri